Study of the Disease Process of Lymphangioleiomyomatosis

StatusRecruiting
PhaseNot specified
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗

Record History

The 50 most recent of 383 record versions are accounted for below. See every version on ClinicalTrials.gov ↗

  1. Re-verified, no change to tracked fields
  2. Re-verified, no change to tracked fields
  3. Re-verified, no change to tracked fields
  4. Re-verified, no change to tracked fields
  5. Eligibility criteria expanded, about 1 word
Show 45 earlier versionsHide 45 earlier versions
  1. 3 versions Re-verified since Aug 26, 2026, no change to tracked fieldsv376-v378
  2. Eligibility criteria expanded, about 152 wordsv375
  3. Study Status, Study Description, Eligibilityv374
  4. 40 versions Re-verified since Feb 26, 2025, no change to tracked fieldsv334-v373
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Pulmonary lymphangioleiomyomatosis (LAM) is a destructive lung disease typically affecting women of childbearing age. Currently, there is no effective therapy for the disease and the prognosis is poor. This study is designed to determine the disease processes involved at the level of cells and molecules, in order to develop more effective therapy. Researchers intend to identify the proteins and genes that contribute to the process of lung destruction in affected individuals.
Trial Details
NCT Number NCT00001465
Lead Sponsor National Heart, Lung, and Blood Institute (NHLBI)
Conditions
(from sponsor)		 Lung Disease, Pneumothorax, Tuberous Sclerosis, Lymphangioleiomyomatosis
Related terms Lung Diseases, Lymphangioleiomyomatosis, Pneumothorax, Tuberous Sclerosis
Enrollment 2,000 participants
Start Date
Updated on ClinicalTrials.gov